RS51313B - Retard tablete sa hidromorfonom - Google Patents

Retard tablete sa hidromorfonom

Info

Publication number
RS51313B
RS51313B RSP-2010/0084A RSP20100084A RS51313B RS 51313 B RS51313 B RS 51313B RS P20100084 A RSP20100084 A RS P20100084A RS 51313 B RS51313 B RS 51313B
Authority
RS
Serbia
Prior art keywords
active agent
layer
hydromorphon
hydromorphone
release
Prior art date
Application number
RSP-2010/0084A
Other languages
English (en)
Inventor
Marc Zingraff
Markus Reher
Original Assignee
Acino Pharma Ag.51311
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51313(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acino Pharma Ag.51311 filed Critical Acino Pharma Ag.51311
Publication of RS51313B publication Critical patent/RS51313B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)

Abstract

Tableta sa jezgrom tablete koje se sastoji od više peleta, koje sadrže aktivnu materiju, i jedne ili više farmaceutski podnošljivih pomoćnih supstanci i najmanje jednog sloja nanetog na jezgro tablete, pri čemu pelete, koje sadrže aktivnu materiju, sadrže hidromorfon kao aktivnu materiju ili njegovu so ili solvat i imaju sledeću strukturu:a) inertno jezgro,b) sloj aktivne materije nanet na inertno jezgro,c) sloj nanet na sloj aktivne materije koji odlaže oslobadjanje aktivne materije, id) još jedan sloj aktivne materije na sloju, koji odlaže oslobadjanje aktivne materije.Prijava sadrži još 9 patentnih zahteva.
RSP-2010/0084A 2007-11-09 2007-11-09 Retard tablete sa hidromorfonom RS51313B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021788A EP2057984B1 (de) 2007-11-09 2007-11-09 Retardtabletten mit Hydromorphon

Publications (1)

Publication Number Publication Date
RS51313B true RS51313B (sr) 2010-12-31

Family

ID=39272211

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0084A RS51313B (sr) 2007-11-09 2007-11-09 Retard tablete sa hidromorfonom

Country Status (15)

Country Link
US (1) US20100247647A1 (sr)
EP (3) EP2057984B1 (sr)
JP (1) JP2011503017A (sr)
AT (2) ATE455538T1 (sr)
AU (1) AU2008324466A1 (sr)
CA (1) CA2704646C (sr)
DE (1) DE502007002695D1 (sr)
DK (2) DK2057984T3 (sr)
ES (2) ES2337935T3 (sr)
HR (1) HRP20100157T1 (sr)
PL (1) PL2057984T3 (sr)
PT (1) PT2057984E (sr)
RS (1) RS51313B (sr)
SI (1) SI2057984T1 (sr)
WO (1) WO2009059701A2 (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389235C (en) 1999-10-29 2007-07-17 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
CA2784407A1 (en) 2009-12-17 2011-07-14 Cima Labs Inc. Abuse-resistant formulations
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
EP2446882B8 (de) * 2010-10-28 2014-02-12 Acino Pharma AG Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
KR102127625B1 (ko) * 2012-09-03 2020-06-29 다이이찌 산쿄 가부시키가이샤 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3229788A4 (en) 2014-12-08 2018-06-13 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
KR20200093608A (ko) 2017-11-27 2020-08-05 디에스엠 아이피 어셋츠 비.브이. 냉동-건조된 다중미립자 고체 투여 형태
TW201943410A (zh) 2018-04-10 2019-11-16 荷蘭商帝斯曼知識產權資產管理有限公司 具有彈性結構之多顆粒固體劑型
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
JP2007520421A (ja) * 2003-06-26 2007-07-26 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 経口投与用放出制御型薬物送達システム
CA2874604A1 (en) * 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20070104789A1 (en) * 2005-11-04 2007-05-10 Donald Spector Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
US20070207200A1 (en) * 2006-03-06 2007-09-06 Pozen Inc. Dosage forms for administering combinations of drugs

Also Published As

Publication number Publication date
DK2057984T3 (da) 2010-05-03
EP2057984B1 (de) 2010-01-20
ES2374690T3 (es) 2012-02-21
PT2057984E (pt) 2010-03-10
SI2057984T1 (sl) 2010-04-30
ATE455538T1 (de) 2010-02-15
DK2217210T3 (da) 2012-02-13
JP2011503017A (ja) 2011-01-27
HRP20100157T1 (hr) 2010-04-30
EP2425822B1 (de) 2012-12-19
CA2704646A1 (en) 2009-05-14
EP2217210B1 (de) 2011-12-14
EP2425822A1 (de) 2012-03-07
AU2008324466A1 (en) 2009-05-14
ES2337935T3 (es) 2010-04-30
WO2009059701A3 (de) 2009-07-16
US20100247647A1 (en) 2010-09-30
ATE536862T1 (de) 2011-12-15
EP2057984A1 (de) 2009-05-13
DE502007002695D1 (de) 2010-03-11
WO2009059701A2 (de) 2009-05-14
CA2704646C (en) 2016-04-05
PL2057984T3 (pl) 2010-05-31
EP2217210A2 (de) 2010-08-18

Similar Documents

Publication Publication Date Title
PL2057984T3 (pl) Tabletki z hydromorfonem o przedłużonym uwalnianiu
DK1631251T3 (da) Tablet til forsinket frigørelse med defineret kernegeometri
WO2008039291A3 (en) Dosage forms for tamper prone therapeutic agents
RS54929B1 (sr) Formulacija i metod obložene tablete
WO2009113703A3 (en) Orally-disintegrating solid preparation
MXPA05012637A (es) Tableta de liberacion modificada del clorhidrato de bupropion.
MX2010003304A (es) Suplemento alimenticio granular.
WO2009025063A1 (ja) 離型用シート
EP1928431B8 (en) Controlled release pharmaceutical composition containing carvedilol
WO2007072495A3 (en) Coated tablets having prolonged gastric retention
UA88509C2 (ru) Сублингвальная таблетка с покрытием, которое содержит опиоидный анальгетик
ZA200803502B (en) Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof
NO20052400L (no) Kontrollert frigivelsespreparat
CL2009000550A1 (es) Metodo para mantener el estado de latencia de una semilla y evitar la germinacion de la misma que comprende revestir dicha semilla con una composicion que comprende particulas que contienen un material de nucleo, el cual comprende un material de cambio de fase.
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
WO2011077239A3 (en) Slow release pharmaceutical compositions of iloperidone
NO20052515D0 (no) Frigjoringskontrollerte sammensetninger
WO2012091408A3 (en) Matrix type antimicrobial vehicle and manufacturing method thereof
TW200617943A (en) Layer jump on a multi-layer disc
CL2007002054A1 (es) Sistema de proteccion para tuberias que comprende un recubrimiento que contiene copolimero de un polimero de hidrocarburo alquilo sustituido en combinacion con un polimero de dieno y una cinta para cubrir dicho recubrimiento, compuesto por un respald
EP2486917A4 (en) COATING FILM AND GRANULES AND TABLETS THEREWITH
WO2011090725A3 (en) Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
WO2007143959A3 (en) Tablet containing metformin
DE502005010444D1 (de) Magnesium-Mikrotabletten mit verzögerter Freisetzung
WO2010023693A3 (en) Controlled release compositions of ropinirole